The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

17 articles for MD Schaber


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a Potent Class of PI3Ka Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT).EBI
Glaxosmithkline
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.EBI
TBA
Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potentß isoform selective phosphatidylinositol 3-kinase inhibitors.EBI
Glaxosmithkline
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.EBI
Merck Research Laboratories
Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.EBI
Merck Research Laboratories
Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors.EBI
Glaxosmithkline
Aminofurazans as potent inhibitors of AKT kinase.EBI
Glaxosmithkline
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.EBI
Merck Research Laboratories
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.EBI
GlaxoSmithKline
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.EBI
Merck Research Laboratories
N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.EBI
Merck Research Laboratories
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.EBI
Merck Research Laboratories
[3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors.EBI
Glaxosmithkline
Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinasesBDB
Hanmi Pharm.
CGRP receptor antagonistsBDB
Heptares Therapeutics
Identification of potent and novel small-molecule inhibitors of caspase-3.BDB
Sunesis Pharmaceuticals
1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitors.BDB
Pharmacor